FDA approves Keytruda-based combination for advanced cervical cancer

The FDA approved pembrolizumab in combination with chemoradiotherapy for the treatment of certain women with stage III to stage IVA cervical cancer.
This is the third approved cervical cancer indication for pembrolizumab (Keytruda, Merck), an anti-PD-1 therapy. The FDA previously approved the agent in combination with chemotherapy, with or without bevacizumab, for the treatment of women with PD-L1-expressing persistent, recurrent, or metastatic cervical cancer and as monotherapy for women with recurrent or metastatic cervical cancer who experienced disease progression while receiving or after

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart